PATENT CLAIM ANALYSIS

Application Number: 16439121
Application Type: Utility
Filing Date: 2019-06
Publication Date: 2019-09
Patent Classification: ["548", "112000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.

Claim (Index 1):
A method of treating pain in a human being suffering from warm complex regional pain syndrome (CRPS) comprising administering neridronic acid in an acid form or a salt form to the human being suffering from warm CRPS and arthritis, wherein the human being has pain in a limb and the treatment is effective in reducing pain in the limb, and wherein the warmth of the affected limb is reduced by at least about 5%.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 100.0
- Lexical Diversity: 1.3
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16366818', '15820305', '15782480', '15703891', '15814745']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6735577928621187
- 35 USC 102 Novelty (BERT): 0.5722840081544047
- Combined Prediction Score: 0.6634304143913473
- Mean Citation Score: 363.653266
- Max Citation Score: 563.0509999999998
- Similarity Product: 323.95816449064006

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test